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G protein–coupled receptor 35 (GPR35) is a poorly charac-
terized orphan G protein-coupled receptor (GPCR), which 
has potential therapeutic value based on its association with 
several diseases, including cancer, inflammatory bowel dis-
ease, diabetes, hypertension, and heart failure.1 Despite 
reports linking it to several endogenous molecules, including 
kynurenic acid2 and the chemokine CXCL17,3 its endogen-
ous ligand and biological function remain undefined.4
Screening has identified a range of high-potency surro-
gate ligands for GPR35, enabling studies into its pharmacol-
ogy and function.5–8 Although 2 antagonists were discovered 
several years ago,9,10 these are highly selective for the human 
orthologue11 and so it has been challenging to conduct robust 
in vivo studies. Nonetheless, several studies have highlighted 
potential roles for GPR35 in the cardiovascular system and 
in cardiovascular disease.
A genome-wide association study that aimed to identify 
novel risk genes for coronary artery disease in a population of 
hypertensive individuals identified an association between a 
GPR35 single-nucleotide polymorphism and coronary artery 
calcification, a risk factor in coronary artery disease.12 GPR35 
has also recently been implicated as a susceptibility gene for 
chemotherapy-induced cardiotoxicity.13 Further genetic evi-
dence for effects of GPR35 in the heart was observed in 12 
patients with chronic heart failure, where GPR35 expression 
was found to be upregulated in myocardial tissue of these 
patients relative to healthy controls.14 In the same study, adeno-
viral vector-mediated overexpression of GPR35 in primary 
rat cardiomyocytes resulted in hypertrophy.14 Furthermore, 
a significant 37.5 mm Hg increase in systolic blood pressure 
was reported in GPR35 knockout mice compared with the 
wild-type background strain.14 These data strongly suggest 
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BACKGROUND
The orphan receptor G protein–coupled receptor 35 (GPR35) has been 
associated with a range of diseases, including cancer, inflammatory bowel 
disease, diabetes, hypertension, and heart failure. To assess the potential 
for GPR35 as a therapeutic target in cardiovascular disease, this study inves-
tigated the cardiovascular phenotype of a GPR35 knockout mouse under 
both basal conditions and following pathophysiological stimulation.
METHODS
Blood pressure was monitored in male wild-type and GPR35 knockout mice 
over 7–14 days using implantable telemetry. Cardiac function and dimen-
sions were assessed using echocardiography, and cardiomyocyte morph-
ology evaluated histologically. Two weeks of angiotensin II (Ang II) infusion 
was used to investigate the effects of GPR35 deficiency under pathophysio-
logical conditions. Gpr35 messenger RNA expression in cardiovascular tis-
sues was assessed using quantitative polymerase chain reaction.
RESULTS
There were no significant differences in blood pressure, cardiac func-
tion, or cardiomyocyte morphology in GPR35 knockout mice compared 
with wild-type mice. Following Ang II infusion, GPR35 knockout mice 
were protected from significant increases in systolic, diastolic, and 
mean arterial blood pressure or impaired left ventricular systolic func-
tion, in contrast to wild-type mice. There were no significant differences 
in Gpr35 messenger RNA expression in heart, kidney, and aorta follow-
ing Ang II infusion in wild-type mice.
CONCLUSIONS
Although GPR35 does not appear to influence basal cardiovascular 
regulation, these findings demonstrate that it plays an important 
pathological role in the development of Ang II–induced hyper-
tension and impaired cardiac function. This suggests that GPR35 
is a potential novel drug target for therapeutic intervention in 
hypertension.
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that GPR35 plays an important role in blood pressure regu-
lation. In neonatal mouse cardiomyocytes, both Gpr35 mes-
senger RNA and cell-surface protein levels were reported to 
increase in response to hypoxia and hypoxia-inducible factor 
1 activation.15 Gpr35 expression was induced in the myocar-
dium of experimental mouse models of myocardial infarction 
and pathological hypertrophy, and preceded cardiac remod-
eling and heart failure. Furthermore, Gpr35 overexpression in 
mouse cardiomyocytes led to membrane ruffling and forma-
tion of retraction fibers, with no apparent change in cell size.15 
However, the lack of GPR35 antagonists with efficacy at the 
rodent orthologues has hindered a more detailed understand-
ing of these findings in rodent in vivo models.
GPR35 gene expression has been detected in human pri-
mary vascular smooth muscle cells and endothelial cells 
from saphenous vein, and GPR35 agonists induced actin 
fiber reorganization and migration in vascular smooth mus-
cle cells.16 These effects were blocked by the specific GPR35 
antagonists CID-2745687 and ML-145 and by inhibitors of 
Ras homolog gene family, member A (RhoA) signaling path-
way components, indicating that endogenous GPR35 medi-
ates its effects in vascular cells through coupling to Gα13, 
as previously described in GPR35-overexpressing HEK293 
cells.17 This suggests a potential role for GPR35 in the regula-
tion of vascular remodeling, which occurs in intimal hyper-
plasia, restenosis, and vein graft failure.
The emerging roles of GPR35 in the cardiovascular sys-
tem may implicate it as a novel contributor to cardiovascular 
dysfunction and a potential therapeutic target in cardio-
vascular disease, especially in hypertension and heart fail-
ure.1 Although GPR35 has been linked with cardiovascular 
disease, and a GPR35 knockout mouse has been reported 
to have an abnormal blood pressure phenotype, the conse-
quences of GPR35 deficiency on cardiovascular function are 
yet to be examined thoroughly. Therefore, we investigated 
the cardiovascular phenotype of a GPR35 knockout mouse 
in detail under basal physiological conditions and following 
pathological stimulation via angiotensin II (Ang II) infusion.
METHODS
Experimental animals
Animals were housed under 12-hour light/dark cycles 
(0700–1900 light, 1900–0700 dark) at ambient temperature 
and maintained on normal chow (Special Diet Services), 
with drinking water provided ad libitum. All animals used for 
experimental procedures were adult, male, F2 homozygous 
littermates (C57BL/6 or GPR35 KO; a gift from Novartis). 
Genotypes of F2 offspring were determined by end-point 
polymerase chain reaction using primers: Gpr35 forward: 5′ 
ATCGCATGCACCAGTGGACAGAGAC 3′; Neo forward: 
5′ GACGAGTTCTTCTGAGGGGATCGATC 3′; Gpr35 
reverse: 5′ GGTCCACAGCAATGGCAGTGACCAG 3′. All 
procedures were conducted in accordance with the Animals 
(Scientific Procedures) Act 1986 under project license 
60/4286, held by Dr. Delyth Graham.
Animals were randomly allocated to treatment groups 
(n = 8 for wild-type vs. knockout study and n = 6 for Ang 
II infusion model), and the experimenter was blinded to 
treatments during the study and analysis. If telemetry read-
ings were outside of the physiological blood pressure range 
(due to technical error such as displacement of the probe) at 
any time during data collection, the entire data set for that 
animal was excluded prior to unblinding.
Blood pressure monitoring by telemetry
PhysioTel PA-C10 pressure transmitters (DSI, St Paul, 
MN) were surgically implanted into 12- to 13-week-old mice, 
with the transmitter positioned subcutaneously on the right 
shoulder and the catheter inserted into the left carotid artery, 
as previously described.18 Transmitters were calibrated to 
verify accuracy to within 3  mm Hg before implantation. 
Recovery surgery was performed under aseptic conditions, 
and animals were anaesthetized with 2.5% isoflurane and 
1.5 l/min O2 throughout the procedure. Following implant-
ation, animals were administered with analgesic (5  mg/kg 
carprofen), recovered in a heated incubation box until fully 
conscious and monitored daily by weighing to assess post-
operative health. Following a 7-day recovery period, trans-
mitters were remotely switched on and measurements were 
recorded every 5 minutes for the duration of the study using 
the Dataquest IV Telemetry System (DSI). These measure-
ments were used to calculate 24-hour means and daytime 
and nighttime means based on the 12-hour light/dark cycle.
Echocardiography
Cardiac function was assessed using M-mode echocar-
diography, as previously described.19 Animals were anaes-
thetized with 1 l/min 1.5% isoflurane and 1.5 l/min O2 
throughout the procedure. Images were obtained using a 
Siemens Acuson Sequoia 512 ultrasound unit with an 18LS 
probe set at a frequency of 14 MHz. Left ventricular (LV) 
dimensions during systole and diastole were measured using 
ImageJ software. Measurements were taken from 9 separate 
cardiac cycles over 3 different images. Fractional shortening 
(FS), end systolic volume, end diastolic volume, and ejection 
fraction (EF) were calculated using the following equations:
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Where LVEDD  =  LV end diastolic dimension (cm) and 
LVESD  =  LV end systolic dimension (cm). End systolic 
volume and end diastolic volume were derived using the 
Teichholz method.20
Subcutaneous infusion of Ang II
Ang II was administered by subcutaneous infusion using 
ALZET micro-osmotic pumps (Model 1002; Charles River, 
Wilmington, MA). Infusion commenced at 13–14 weeks 
of age (7  days after telemetry implantation) and continued 
for 2 weeks until sacrifice. Ang II human (Sigma-Aldrich, 
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Gillingham, United Kingdom) was dissolved in water and 
sterilized through a 0.2  µm filter. Pumps were filled with 
the appropriate concentration of Ang II to deliver a dose of 
400 ng/kg/min (24 µg/kg/h)21 at a flow rate of 0.25 µl/h. After 
filling, pumps were primed in sterile saline overnight at 37 °C, 
then subcutaneously implanted in the left flank (the oppos-
ite side to the telemetry probe) under aseptic conditions, fol-
lowed by administration of analgesic (5 mg/kg carprofen).
Histological assessment of cardiomyocyte diameter
Wheat germ agglutinin was used to stain cardiomyo-
cyte cell membranes. Tissues were fixed in 10% formalin 
at sacrifice. Following deparaffinization and dehydration, 
5  µm heart (left ventricle + septum) sections were washed 
in running tap water for 5 minutes. Antigen retrieval was 
performed by heating with 10  mM sodium citrate solution 
(pH 6) with 0.1% (v/v) Tween 20 for 10 min, then sections 
were cooled to room temperature before blocking in 1% (v/v) 
goat serum + 5% (w/v) BSA for 1 hour at room temperature. 
Sections were then incubated with 10  µg/ml wheat germ 
agglutinin conjugated to Alexa Fluor 555 (Thermo Fisher 
Scientific, Waltham, MA) for 1 hour at room temperature pro-
tected from light. Sections were washed for 2 × 5 minutes in 
PBS, then mounted with ProLong Gold anti-fade reagent with 
DAPI (Thermo Fisher Scientific) and dried overnight at room 
temperature. DAPI and Alexa Fluor 555 images were taken 
with a ×40 objective on an Olympus BX40 microscope using 
a QImaging QICAM Fast 1394 camera. The experimenter was 
blinded to treatment groups during imaging and analysis. 
Cardiomyocyte width (the longest axis of a transversely ori-
entated cardiomyocyte) was measured using ImageJ software. 
Figure 1. Mean arterial pressure, cardiac mass and cardiomyocyte morphology in GPR35 KO mice under physiological conditions. (a) Mean arterial 
pressure over 7 days in wild-type (black circles) and GPR35 KO (gray squares) mice. Data are 12-hour means representing night (N) and day (D) periods; 
n = 6 (wild type) or n = 8 (GPR35 KO). (b) Whole heart and LV + S mass determined at sacrifice and normalized to tibia length; n = 8. (c) Representative 
M-mode echocardiography images taken on the longitudinal axis at the level of the papillary muscle (scale bar = 3 mm) and ejection fraction calculated 
from LV dimensions; n = 5 (wild type) or n = 8 (GPR35 KO). (d) Transverse heart sections stained with fluorescently tagged wheat germ agglutinin (scale 
bar = 30 µm) and cell diameter quantified as the width of cardiomyocytes orientated on the short axis; n = 5. Data are mean ± SEM, compared using 2-way 
repeated measures analysis of variance (a) or 2-tailed unpaired t test (b–d); no significant differences were found. Abbreviations: GPR35 KO, G protein–
coupled receptor 35 knockout; LV, left ventricular; S, septum.
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Approximately 50 cells from 4 fields of view were measured 
per animal, using a grid system to minimize bias.
Gene expression analysis
Tissues were snap-frozen in liquid nitrogen at sacrifice and 
stored at −80 °C. To lyse heart and kidney tissue, 30–50 mg of 
tissue was transferred to an RNase-free microcentrifuge tube 
with 700  µl QIAzol (QIAGEN, Hilden, Germany) and two 
3  mm tungsten carbide beads. Tissues were homogenized 
for 2 ×  1 minutes in a QIAGEN TissueLyser. To lyse aorta 
tissue, tissue was cooled in liquid nitrogen and crushed to 
a fine powder using a mortar and pestle cooled on dry ice, 
then lysed by the addition of QIAGEN RTL buffer contain-
ing 1% (v/v) β mercaptoethanol and homogenized using a 
QIAshredder spin column (QIAGEN). RNA extraction was 
performed immediately following lysis using the miRNe-
asy Mini Kit (QIAGEN) (heart and kidney) or the RNeasy 
Fibrous Tissue Mini Kit (QIAGEN) (aorta). One microgram 
of RNA was reverse transcribed to complementary DNA using 
TaqMan Reverse Transcription Reagents (Life Technologies). 
qRT-polymerase chain reaction was performed using 
Applied Biosystems TaqMan Gene Expression Assays for 
Gpr35 (Mm01973686_s1), Angiotensin receptor type 1a 
(Agtr1a) (Mm0061671_m1), and Ppib (Mm00478295_m1) 
(Life Technologies). Plates were read on a QuantStudio Flex 
Real-Time PCR System (Thermo Fisher Scientific) and com-
parative cycle threshold (CT) values were obtained using 
QuantStudio Flex software (Thermo Fisher Scientific). ΔCT 
values were calculated (ΔCT = CT for Ppib − CT for Gpr35). 
These were analyzed using the 2−ΔΔCT method,22 in which 
ΔCT values are compared with those of an appropriate con-
trol to generate ΔΔCT values and relative quantification (RQ) 
values (RQ = 2−ΔΔCT). SEs are expressed as RQmin (RQmin = 2−
(ΔΔCT + SEM)) and RQmax (RQmax = 2−(ΔΔCT − SEM)).
Statistical analysis
Statistical analyses were carried out using Graphpad 
Prism software. Normal data distribution was confirmed 
using Shapiro–Wilk test, and data were therefore compared 
using 2-tailed unpaired Student’s t test. Hemodynamic meas-
urements made by telemetry were compared using 2-way 
repeated measures analysis of variance (basal GPR35 knock-
out study) or Student’s t test on the slope of the linear regres-
sion calculated for individual animals (Ang II infusion study).
RESULTS
Blood pressure and cardiac function in the GPR35 knockout 
mouse under physiological conditions
Systolic, diastolic, and mean arterial blood pressure 
(MAP) were not significantly altered in GPR35 knockout 
mice vs. the wild-type strain over a 7-day period (P = 0.127; 
mean MAP 102  ±  3 and 108  ±  3  mm Hg, respectively; 
Figure 1a and Table 1). LV dimensions, FS, and EF were not 
significantly altered in GPR35 knockout mice vs. wild type 
(Figure 1c and Table 2). Cardiac mass and cardiomyocyte 
morphology were not significantly altered in GPR35 
knockout mice vs. wild type (Figure 1b and d).
Blood pressure and cardiac function in the GPR35 knockout 
mouse following Ang II infusion
In wild-type mice, Ang II infusion induced a steady 
increase in MAP of 17  mm Hg over the 2-week period 
(Figure  2a and Table  3). Mean arterial pressure at day 14 
and the slope of the change over time were both significantly 
increased for wild-type mice infused with Ang II compared 
with those infused with water, with a difference in MAP at 
day 14 of 21.1 ± 4.7 mm Hg (P < 0.001) and a mean increase 
of 1.29 ± 0.33 mm Hg/day (P < 0.01; Figure 2a and b and 
Table 3). Systolic and diastolic blood pressure followed the 
same pattern (Table 3).
Table 1. Blood pressure in wild-type and GPR35 knockout mice 
under physiological conditions
Measurement Wild type GPR35 KO P value
Systolic blood pressure (mean over 7 days), mm Hg
 Overall 112 ± 3 117 ± 3 0.201
 Daytime 109 ± 3 111 ± 3 0.242
 Nighttime 117 ± 3 122 ± 2 0.178
Diastolic blood pressure (mean over 7 days), mm Hg
 Overall 93 ± 3 101 ± 3 0.116
 Daytime 88 ± 3 97 ± 4 0.153
 Nighttime 97 ± 3 105 ± 3 0.086
Mean arterial pressure (mean over 7 days), mm Hg
 Overall 102 ± 3 108 ± 3 0.127
 Daytime 97 ± 3 104 ± 3 0.165
 Nighttime 107 ± 3 113 ± 2 0.101
Data are mean ± SEM of n = 6 (wild type) or n = 8 (GPR35 KO), 
compared using 2-tailed repeated measures analysis of variance 
(wild type vs. GPR35 KO); no significant differences were found. 
Abbreviation: GPR35 KO, G protein–coupled receptor 35 knockout.
Table 2. Echocardiographic parameters in wild-type and GPR35 
knockout mice under physiological conditions
 Dimension Wild type GPR35 KO P value
 LV wall thickness, mm 0.84 ± 0.13 0.87 ± 0.05 0.807
 LV systolic diameter, mm 1.43 ± 0.14 1.53 ± 0.08 0.513
 LV diastolic diameter, mm 3.06 ± 0.10 3.12 ± 0.06 0.629
 Fractional shortening, % 53.5 ± 3.1 51.3 ± 1.8 0.540
 End systolic volume, µl 8.98 ± 2.68 10.30 ± 1.37 0.637
 End diastolic volume, µl 75.23 ± 7.48 78.91 ± 4.67 0.667
 Ejection fraction, % 88.7 ± 2.2 87.2 ± 1.3 0.549
Data are mean ± SEM of n = 5 (wild type) or n = 8 (GPR35 KO), 
compared using 2-tailed unpaired t test (wild type vs. GPR35 KO); 
no significant differences were found. Abbreviations: GPR35 KO, G 
protein–coupled receptor 35 knockout; LV, left ventricular.
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In GPR35 knockout mice, no Ang II–induced increases 
in MAP, systolic, or diastolic blood pressure were observed 
(Figure 2c and d and Table 3). There were no significant dif-
ferences between Ang II- and water-infused mice in MAP at 
day 14 or the slope of the change over time, with a difference 
in MAP at day 14 of 7.2 ± 7.8 mm Hg (P = 0.376) and a mean 
slope of 0.12 ± 0.24 mm Hg/day (P = 0.638; Figure 2c and d 
and Table 3).
In wild-type mice, LV wall thickness and diameter were 
unchanged after either water or Ang II infusion (Table  4); 
however, in wild-type mice infused with Ang II, FS and EF 
were significantly reduced on day 14 compared with day 0 (by 
6.3 ± 2.2% and 5.7 ± 2.1%, respectively; both P < 0.05; Figure 3a 
and Table  4). The changes in FS and EF in wild-type Ang 
II-infused mice were significant when compared with those in 
water-infused mice (both P < 0.05; Figure 3a and Table 4).
In GPR35 knockout mice, none of the echocardiographic 
measurements taken were significantly different on day 14 
compared with day 0 (Table 4). The changes in FS and EF 
were close to 0% in both water- and Ang II-infused GPR35 
knockout mice and were not significantly different between 
groups (Figure 3b and Table 4).
Ang II infusion did not significantly affect whole heart 
or LV mass in either wild-type or GPR35 knockout mice 
(Figure 3c and e). There was also no detectable induction 
of hypertrophy at the cellular level, with no significant 
increase in cardiomyocyte diameter observed in either 
strain (Figure 3d and f). There were no differences in peri-
vascular or interstitial cardiac fibrosis (Supplementary 
Figure 1a and b).
Gpr35 expression in the heart, aorta, and kidney tis-
sue of the wild-type mice infused with Ang II was not 
significantly different to that of the water-infused mice 
(Figure 4a). Expression of Agtr1a was not significantly dif-
ferent between any 2 groups, except between water-infused 
wild-type mice and GPR35 knockout mice in the heart 
(1.3-fold higher expression of Agtr1a in GPR35 knock-
out; Figure  4b). There were no differences in vascular 
remodeling, renal mass, or renal fibrosis (Supplementary 
Figures 2 and 3).
Figure 2. Change in mean arterial blood pressure in wild-type and GPR35 KO mice during 2-week Ang II infusion. Mean arterial blood pressure in (a,b) 
WT or (c,d) GPR35 KO mice. Baseline measurements were taken on day 0 prior to minipump implantation (indicated by dotted line). (a,c) 12-hour means 
representing night (N) and day (D) periods. (b,d) Change over 14 days presented as slope of the linear regression (mm Hg/day) for each individual animal. 
Data are mean ± SEM of n = 7 (except GPR35 KO + water, n = 5). **P < 0.01, compared using 2-tailed unpaired t test (water vs. Ang II on day 14). ##P < 0.01, 
compared using 2-tailed unpaired t test (water vs. Ang II). Abbreviations: Ang II, angiotensin II; GPR35, G protein–coupled receptor 35; KO, knockout; ns, 
not significant; WT, wild type.
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DISCUSSION
The data presented here demonstrate that under physio-
logical conditions, there are no significant differences in 
hemodynamic parameters, cardiac function, or cardiac 
morphology in GPR35 knockout mice compared with the 
wild-type background strain. However, under the patho-
logical conditions of Ang II infusion, GPR35 knockout mice 
were protected from Ang II–induced increases in blood 
pressure and impairment of cardiac function.
The finding that GPR35 knockout mice have a normal 
blood pressure phenotype under basal conditions contrasts 
Table 3. Blood pressure in wild-type and GPR35 knockout mice following 2-week Ang II infusion
Group Day 0 Day 14
Day 14, 
P value
Slope, 
mm Hg/day
Slope, 
P value
Systolic blood pressure, mm Hg
 Wild type + water 123 ± 3 120 ± 3 0.002** −0.13 ± 0.20 0.004**
 Wild type + Ang II 125 ± 1 145 ± 5 1.42 ± 0.39
 GPR35 KO + water 114 ± 2 133 ± 7 0.289 0.39 ± 0.35 0.672
 GPR35 KO + Ang II 121 ± 4 123 ± 5 0.16 ± 0.36
Diastolic blood pressure, mm Hg
 Wild type + water 94 ± 1 95 ± 4 0.015* 0.11 ± 0.15 0.003**
 Wild type + Ang II 97 ± 1 112 ± 5 1.24 ± 0.27
 GPR35 KO + water 93 ± 2 99 ± 7 0.758 0.79 ± 0.34 0.195
 GPR35 KO + Ang II 97 ± 4 97 ± 4 0.22 ± 0.25
Mean arterial pressure, mm Hg
 Wild type + water 108 ± 2 107 ± 3 0.002** −0.03 ± 0.17 0.004**
 Wild type + Ang II 111 ± 1 128 ± 5 1.29 ± 0.33
 GPR35 KO + water 102 ± 2 105 ± 7 0.588 0.58 ± 0.35 0.283
 GPR35 KO + Ang II 109 ± 3 109 ± 4 0.12 ± 0.24
Data are mean ± SEM of n = 7 (except GPR35 KO + water, n = 5). *P < 0.05, **P < 0.01, compared using 2-tailed unpaired t test (water vs. 
Ang II). Abbreviations: Ang II, angiotensin II; GPR35, G protein–coupled receptor 35; KO, knockout.
Table 4. Echocardiographic parameters in wild-type and GPR35 knockout mice following 2-week Ang II infusion
 Measurement Water Ang II P value
 Wild type
 Δ LV wall thickness, mm 0.12 ± 0.09 0.02 ± 0.07 0.422
 Δ LV systolic diameter, mm 0.02 ± 0.10 0.16 ± 0.13 0.422
 Δ LV diastolic diameter, mm 0.07 ± 0.17 −0.05 ± 0.17 0.624
 Δ Fractional shortening, % 0.41 ± 1.59 −6.26 ± 2.22 0.027*
 Δ End systolic volume, µL 0.19 ± 1.82 2.83 ± 2.61 0.406
 Δ End diastolic volume, µL 6.32 ± 12.07 −3.72 ± 12.07 0.576
 Δ Ejection fraction, % 0.32 ± 1.22 −4.97 ± 1.80 0.027*
 GPR35 KO
 Δ LV wall thickness, mm 0.03 ± 0.10 0.09 ± 0.11 0.592
 Δ LV systolic diameter, mm 0.07 ± 0.08 −0.22 ± 0.15 0.112
 Δ LV diastolic diameter, mm 0.11 ± 0.12 −0.36 ± 0.18 0.057
 Δ Fractional shortening, % −0.85 ± 1.25 1.40 ± 3.30 0.539
 Δ End systolic volume, µL 1.37 ± 1.62 −4.39 ± 2.91 0.115
 Δ End diastolic volume, µL 9.14 ± 9.17 −25.26 ± 12.89 0.054
 Δ Ejection fraction, % −0.56 ± 0.92 1.07 ± 2.52 0.557
Data are mean ± SEM of change from baseline at day 14 of (wild type: n = 6–8; GPR35 KO: n = 6). *P < 0.05, compared using 2-tailed 
unpaired t test (water vs. Ang II). Abbreviations: Ang II, angiotensin II; GPR35, G protein–coupled receptor 35; KO, knockout; LV, left ventricular.
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with a previous study in such mice, which reported a sys-
tolic blood pressure 37.5 mm Hg higher than wild-type lit-
termates.14 There are several reasons why these 2 studies 
might have had such different findings, stemming from the 
fact that they employed 2 different methods of measuring 
blood pressure. Min et al. used Millar catheterization to rec-
ord hemodynamic parameters at a single time-point under 
terminal anesthesia, whereas in this study, blood pressure 
was monitored continuously via telemetry for 7 days in con-
scious animals. In addition, the age and/or sex of the mice 
may have influenced the results. As in the majority of cardio-
vascular studies of animal models not examining sex differ-
ences, this study was performed on young adult male mice to 
avoid potential confounding effects of hormonal variation. 
It is therefore possible that a high blood pressure phenotype 
may manifest in female or aged mice and it will be important 
to study female mice in the future.
LV global systolic function, cardiac mass, cardiomyocyte 
morphology, cardiac fibrosis, renal mass, renal fibrosis, and 
vascular remodeling in GPR35 knockout mice were found 
Figure 3. Ejection fraction, cardiac mass, and cardiomyocyte morphology in wild-type and GPR35 KO mice following 2-week Ang II infusion. (a,b) 
Change from baseline at day 14 in ejection fraction calculated from LV dimensions of (a) WT (n = 6–8) and (b) GPR35 KO mice (n = 6). (c,e) Whole heart 
and LV + S mass of (c) WT and (e) GPR35 KO mice determined at sacrifice and normalized to tibia length; n = 7. (d,f) Cell diameter in transverse heart sec-
tions from (d) WT and (f ) GPR35 KO mice quantified by measuring the width of cardiomyocytes orientated on the short axis; n = 5. Data are mean ± SEM, 
compared using 2-tailed unpaired t test; no significant differences were found. Abbreviations: Ang II, angiotensin II; GPR35, G protein–coupled receptor 
35; KO, knockout; LV, left ventricular; S, septum; WT, wild type.
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to be comparable to those in wild-type mice. As GPR35 
expression in the heart has been linked to adverse cardiac 
remodeling, and heterologous overexpression of GPR35 has 
been shown to drive cardiomyocyte hypertrophy, one might 
expect GPR35 knockout mice to have altered cardiac mass, 
structure, or function.14,15 However, GPR35 expression in 
the heart was previously reported following coronary artery 
ligation or transaortic constriction, or was upregulated in 
response to hypoxia-inducible factor 1 activation.15 This 
suggests that induction of GPR35 expression depends on 
the pathophysiological status, which may explain the lack 
of an abnormal cardiac phenotype in GPR35 knockout mice 
under physiological conditions.
To investigate the role of GPR35 in the context of cardio-
vascular disease, we studied the cardiovascular phenotype of 
the GPR35 knockout mouse in an Ang II infusion hyper-
tension model. GPR35 knockout mice were resistant to the 
development of Ang II–induced hypertension, suggesting 
an important role for GPR35 in hypertensive signaling. 
Gene expression analysis demonstrated that this resistance 
was not due to Agtr1a downregulation in GPR35 knockout 
mice. There is currently no evidence that GPR35 interacts 
directly with Ang II, Agtr1, or other renin–angiotensin sys-
tem components. Furthermore, there is very low expression 
of GPR35 relative to renin–angiotensin system components 
in key tissues.23 Therefore, it is unknown whether GPR35 
exerts effects on Ang II–induced hypertension via renin–
angiotensin system modulation. The loop diuretic drugs 
bumetanide and furosemide are reported to be human, but 
not rodent, GPR35 agonists,24 highlighting that future stud-
ies into GPR35 function may identify novel interactions 
between GPR35, the renin–angiotensin system, and kidney 
in blood pressure regulation. Furthermore, since the central 
nervous system is also integral to blood pressure regulation 
following Ang II infusion, investigation of GPR35 in the 
brain would also be interesting in the future. Such studies 
would be greatly facilitated by availability of selective and 
potent rodent GPR35 agonists and antagonists.
GPR35 couples selectively to Gα1317,25 and regulates 
actin reorganization in both cardiomyocytes and vascu-
lar smooth muscle cells.14–16 In rodent neonatal and human 
HL-1 cardiomyocytes, direct overexpression of GPR35 
altered actin organization and cell morphology.15 Therefore, 
the cardiovascular effects of GPR35 may be mediated by the 
Gα13/RhoA/ROCK pathway. Although our findings conflict 
with a previous study in GPR35 knockout mice, existing evi-
dence of pathological roles for Gα13/RhoA/ROCK signaling 
in the cardiovascular system, including prohypertensive and 
Figure 4. Gpr35 and Agtr1a expression in heart, aorta, and kidney in wild-type and/or GPR35 KO mice following 2-week Ang II infusion. (a) Gpr35 expres-
sion relative to housekeeper Ppib in wild-type mice. Data are mean ± RQmax and RQmin of n = 4; ΔCT values were compared using 2-tailed unpaired t test; 
no significant differences were found. (b) Agtr1a expression relative to housekeeper Ppib in wild-type and GPR35 KO mice. Data are mean ± RQmax and 
RQmin of n = 4; ΔCT values were compared using 1-way ANOVA with Tukey’s multiple comparisons post-test; *P < 0.05. Abbreviations: ANOVA, analysis of 
variance; Ang II, angiotensin II; GPR35, G protein–coupled receptor 35; KO, knockout; WT, wild type.
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prohypertrophic effects, provide a rationale for why GPR35 
knockout mice are protected from cardiovascular disease.26–28 
More in-depth investigation of the activation of these com-
ponents in GPR35 knockout models of cardiovascular dis-
ease may yield insights into potential mechanisms of Ang 
II–induced hypertension resistance in GPR35 knockout mice.
An alternative explanation for these findings is that 
GPR35 interacts with Ang II–mediated blood pressure regu-
lation indirectly through its effects in other tissues. Vascular 
inflammation is now recognized as an important factor in 
Ang II–induced hypertension and associated end-organ 
damage.29,30 Previous studies linking GPR35 with inflamma-
tion provide another potential mechanism by which GPR35 
might contribute to Ang II–induced effects on the cardio-
vascular system.3,31,32 GPR35 expression has been detected 
in spleen, on lymphocytes and on several myeloid cell 
types, as well as in vascular endothelial cells.2,16,32,33 Studies 
with GPR35 agonists have suggested possible roles in pro-
inflammatory cytokine release, macrophage recruitment, 
and leukocyte arrest onto the vascular endothelium.3,31,32 
Therefore, the apparent requirement for GPR35 in Ang 
II–induced hypertension could be due to a function that 
contributes to vascular inflammation. Furthermore, recent 
evidence suggests macrophages originating in the spleen, 
where GPR35 is highly expressed,2 may contribute to Ang 
II–induced cardiac fibrosis and hypertension.34 A  role for 
GPR35 in the prohypertensive immune response is an inter-
esting possibility that has not previously been explored, and 
future studies into the effects of GPR35 on markers of vas-
cular inflammation and release of immune cells from the 
spleen in models of hypertension could yield further insight.
In conclusion, the findings presented here suggest that 
although GPR35 does not appear to influence physiological 
cardiovascular regulation, it plays an important pathological 
role in the development of Ang II–induced hypertension and 
impaired cardiac function, and therefore may contribute to 
cardiovascular disease. Although the mechanism by which 
inactivation of GPR35 attenuates Ang II–induced hyper-
tension remains unclear, this suggests that targeting GPR35 
could be a novel target in the therapeutic control of blood 
pressure, most obviously through the use of GPR35 antago-
nists. The lack of antagonists with affinity for rodent GPR35 
orthologues will make investigating the therapeutic poten-
tial of GPR35 antagonism challenging. Ongoing screening 
efforts (supported by novel bioinformatic approaches for lig-
and identification as well as an improved understanding of 
the mechanisms of species selectivity) may yet yield equipo-
tent GPR35 antagonists that will enable such studies.8,35 It 
is hoped that future studies that assess the effects of GPR35 
antagonism, along with a better understanding of the mech-
anisms involved in these effects, will reveal its true potential 
as a pharmacological target in cardiovascular disease.
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